Iminoglycinuria

Last updated
Iminoglycinuria
Other namesFamilial iminoglycinuria [1] [2] [3]
Imine.png
Imine, a functional group found in imino acids
Specialty Endocrinology   OOjs UI icon edit-ltr-progressive.svg

Iminoglycinuria is an autosomal recessive [4] disorder of renal tubular transport affecting reabsorption of the amino acid glycine, and the imino acids proline and hydroxyproline. [4] [5] This results in excess urinary excretion of all three acids (-uria denotes "in the urine"). [6]

Contents

Iminoglycinuria is a rare and complex disorder, associated with a number of genetic mutations that cause defects in both renal and intestinal transport systems of glycine and imino acids. [4] [7] [8] [9]

Imino acids typically contain an imine functional group, instead of the amino group found in amino acids. Proline is considered and usually referred to as an amino acid, [10] [11] but unlike others, it has a secondary amine. This feature, unique to proline, identifies proline also as an imino acid. [12] [13] Hydroxyproline is another imino acid, made from the naturally occurring hydroxylation of proline. [12]

Presentation

The primary characteristic of iminoglycinuria is the presence of glycine and imino acids in the urine. Otherwise, it is thought to be a relatively benign disorder, [6] [14] although symptoms associated with disruptions of proline and glycine metabolism caused by malabsorption may be present with iminoglycinuria. [4] [15] These include encephalopathy, mental retardation, [2] deafness, [3] blindness, [16] kidney stones, [17] hypertension [18] and gyrate atrophy. [19]

Gyrate atrophy is an inherited degenerative disorder of the retina and choroid, [20] sometimes accompanying the metabolic condition hyperornithinemia. [19] [21] The presence of gyrate atrophy with iminoglycinuria stems from a deficiency of proline in chorioretinal tissues, while processes behind hyperornithinemia disrupt the metabolic pathway from ornithine to proline, which alters the catabolism of ornithine, and also results in reduced levels of proline. Thus, gyrate atrophy can be found with either disorder, with proline deficiency as an underlying feature. [19] [22]

Hyperglycinuria is another disorder affecting reabsorption of glycine and imino acids, similar to iminoglycinuria and considered to be a heterozygous form. [3] [4] When accompanied by a specific type of kidney stone (nephrolithiasis), it is sometimes referred to as "iminoglycinuria, type II". [15] [23] [24]

Genetics

Iminoglycinuria has an autosomal recessive pattern of inheritance. Autorecessive.svg
Iminoglycinuria has an autosomal recessive pattern of inheritance.

Iminoglycinuria is believed to be inherited in an autosomal recessive manner. [4] This means a defective gene responsible for the disorder is located on an autosome, and inheritance requires two copies of the defective gene—one from each parent. Parents of an individual with an autosomal recessive disorder both carry one copy of the defective gene, but usually do not experience any signs or symptoms of the disorder.[ citation needed ]

A non-inherited cause of excess urinary excretion of proline and glycine, similar to that found in iminoglycinuria, is quite common to newborn infants younger than six months. Sometimes referred to as neonatal iminoglycinuria, it is due to underdevelopment of high-affinity transport mechanisms within the renal circuit, specifically PAT2, SIT1 and SLC6A18. The condition corrects itself with age. [4] [25] In cases where this persists beyond childhood, however, inherited hyperglycinuria or iminoglycinuria may be suspected. [4]

Pathophysiology

Glycine, proline and hydroxyproline share common renal tubular mechanisms of reabsorption, [7] a function specific to the proximal tubule. [4] [5] Both reabsorption or absorption of glycine and imino acids takes place respectively at the proximal tubule or intestinal brush border epithelium. The more selective transport of proline and other imino acids is driven at the molecular level by a mammalian cellular transport mechanism aptly known as system IMINO. [5] [26] [27]

Active transport into a cell through ion channels, using the coupling power provided by sodium-potassium exchange Scheme sodium-potassium pump-en.svg
Active transport into a cell through ion channels, using the coupling power provided by sodium-potassium exchange

While no single genetic mutation has been established as the cause of iminoglycinuria; several mutations, affecting transport mechanisms shared by glycine, proline and hydroxyproline, as well as those that selectively transport either glycine or imino acids, including the IMINO system, are known to be associated with the disorder. [4] When combined, these factors will result in a variable phenotype for iminoglycinuria depending on which mutations are present. [4] However, despite the role that intestinal malabsorption of glycine and imino acids can play in iminoglycinuria, the primary defect disrupts their renal transport and reabsorption. [4] [14] This is evident, as inherited iminoglycinuria can be clinically present with no intestinal involvement. [16]

In mammals, including humans, the transport of amino and imino acids from the lumen (interior) of the intestine or the renal proximal tubule into the cells occurs at the brush border membrane of the epithelium (moist, tightly packed cellular lining of many tissues and organs of the body). Here, cotransporters such as sodium or chloride (part of the system of Na-K-Cl cotransporters) couple with the amino or imino acids on the molecular level and transport them through specific integral membrane proteins that form ion channels, which are located within the cell membrane. [27] [28] From the cells, the absorbed or reabsorbed amino and imino acids eventually reach the blood. Absorption refers to the overall process happening in the intestine in lieu of normal digestive breakdown of proteins, while reabsorption refers to the process occurring in the renal proximal tubule to reclaim amino and imino acids that have been filtered out of the blood via the glomerulus.[ citation needed ]

These forms of transport require energy, as the products being transported are usually moving against a higher concentration gradient. This process, called active transport, get its energy from ATP and other ATP-related cotransport systems that produce energy, like the sodium-potassium pump.[ citation needed ]

Mechanism

The primary defect associated with iminoglycinuria is a homozygous (recessive) mutation of the SLC36A2 (PAT2) gene. [4] One of several membrane transport proteins in the solute carrier family of amino acid transporters, PAT2 is the high-affinity renal transporter of glycine, proline and hydroxyproline found to be defective in both alleles when iminoglycinuria is present in an individual. This is in contrast to the fact that when only one PAT2 allele is defective, hyperglycinuria will be present instead of iminoglycinuria. These findings delineate iminoglycinuria as the homozygous form of hyperglycinuria, with the former having a higher degree of urinary excretion of glycine and imino acids correlating to mutations in both alleles. [4] [7]

Another mutation suspected to convey the iminoglycinuria phenotype may be found in the SLC36A1 (PAT1) gene. [29] [30] Identified as the low-affinity intestinal transporter of glycine and imino acids, PAT1 works in cooperation with the renal sodium-hydrogen exchanger NHE3 ( SLC9A3 ). [30] As absorption and reabsorption of glycine, proline and hydroxyproline occurs through PAT1 as well, it is believed to play another role in expressing the malabsorptive iminoglycinuria phenotype. Recent reports, however, suggest a more diminished role from PAT1 in some cases of the disorder. [4] [5] [30] [31]

While PAT2 is strongly indicated as the primary mutagen responsible for iminoglycinuria, the variability of the phenotype is found to be instituted by three modifying genetic mutations. The major one among these is believed to be system IMINO. [4]

Defined as the sodium-dependent proline transporter not inhibited by alanine, system IMINO, believed to be formed by the SLC6A20 (SIT1) gene, is a crucial mammalian transport mechanism responsible for both renal reabsorption and intestinal absorption of proline and other imino acids, such as hydroxyproline and pipecolate. [26] [27] The mRNA sequence for SIT1 is expressed in a great deal of the gastrointestinal tract, including the stomach, duodenum, jejunum, ileum, cecum and colon. It is also found in the kidney, optical choroid, and parts of the central nervous system such the brain and microglial cells. [26]

Reduced penetrance is a phenomenon where a fully inherited genetic trait, such as a disease or disorder, fails to exhibit the expected phenotype. This has been reported in some cases of iminoglycinuria. [4] Here, system IMINO is thought to play a role in reduced penetrance of iminoglycinuria by compensating for imino acid malabsorption related specifically to mutations of PAT2. [4] Conversely, SIT1 mutations are believed to result in full expression of iminoglycinuria in some cases where heterozygous mutations of PAT2 would otherwise have only been sufficient to cause hyperglycinuria. [4]

Two other transport systems are believed to play subsequent roles in iminoglycinuria, when mutations in them are present. The neutral amino acid transporter SLC6A19 (affecting glycine, proline, and other neutral amino acids like cysteine and tryptophan), associated with Hartnup disease, plays a role in iminoglycinuria as a modifier to PAT2 mutations and is also directly affected by the actions of SIT1. [4] [32] The glycine-specific transporter, SLC6A18 , also has an effect on the iminoglycinuria phenotype by either compounding or compensating for failures of glycine transport. [4]

To summarize, iminoglycinuria is primarily expressed by homozygous mutations of the PAT2 renal transporter, while the overall iminoglycinuria phenotype may be modified by normal or defective activity of SIT1 (IMINO), SLC6A19 and SLC6A18. [4]

Diagnosis

Treatment

See also

Related Research Articles

<span class="mw-page-title-main">Collagen</span> Most abundant structural protein in animals

Collagen is the main structural protein in the extracellular matrix of a body's various connective tissues. As the main component of connective tissue, it is the most abundant protein in mammals. 25% to 35% of a mammalian body's protein content is collagen. Amino acids are bound together to form a triple helix of elongated fibril known as a collagen helix. The collagen helix is mostly found in connective tissue such as cartilage, bones, tendons, ligaments, and skin. Vitamin C is vital for collagen synthesis, while Vitamin E improves its production.

<span class="mw-page-title-main">Collagen helix</span> Main protein structure of fibrous collagen

In molecular biology, the collagen triple helix or type-2 helix is the main secondary structure of various types of fibrous collagen, including type I collagen. In 1954, Ramachandran & Kartha advanced a structure for the collagen triple helix on the basis of fiber diffraction data. It consists of a triple helix made of the repetitious amino acid sequence glycine-X-Y, where X and Y are frequently proline or hydroxyproline. Collagen folded into a triple helix is known as tropocollagen. Collagen triple helices are often bundled into fibrils which themselves form larger fibres, as in tendons.

<span class="mw-page-title-main">Imino acid</span> Organic compound

In organic chemistry, an imino acid is any molecule that contains both imine (>C=NH) and carboxyl functional groups.

<span class="mw-page-title-main">Hartnup disease</span> Metabolic disorder

Hartnup disease is an autosomal recessive metabolic disorder affecting the absorption of nonpolar amino acids. Niacin is a precursor to nicotinamide, a necessary component of NAD+.

<span class="mw-page-title-main">Ornithine translocase deficiency</span> Medical condition

Ornithine translocase deficiency, also called hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome, is a rare autosomal recessive urea cycle disorder affecting the enzyme ornithine translocase, which causes ammonia to accumulate in the blood, a condition called hyperammonemia.

<span class="mw-page-title-main">Ornithine aminotransferase</span> Class of enzymes

Ornithine aminotransferase (OAT) is an enzyme which is encoded in human by the OAT gene located on chromosome 10.

<span class="mw-page-title-main">Neutral and basic amino acid transport protein rBAT</span> Protein-coding gene in the species Homo sapiens

Neutral and basic amino acid transport protein rBAT is a protein that in humans is encoded by the SLC3A1 gene.

<span class="mw-page-title-main">Aminomethyltransferase</span> Protein-coding gene in the species Homo sapiens

Aminomethyltransferase is an enzyme that catabolizes the creation of methylenetetrahydrofolate. It is part of the glycine decarboxylase complex.

A neurotransmitter sodium symporter (NSS) (TC# 2.A.22) is type of neurotransmitter transporter that catalyzes the uptake of a variety of neurotransmitters, amino acids, osmolytes and related nitrogenous substances by a solute:Na+ symport mechanism. The NSS family is a member of the APC superfamily. Its constituents have been found in bacteria, archaea and eukaryotes.

<span class="mw-page-title-main">Proton-coupled amino acid transporter 1</span> Protein-coding gene in the species Homo sapiens

Proton-coupled amino acid transporter 1 is a protein that in humans is encoded by the SLC36A1 gene.

<span class="mw-page-title-main">Sodium-dependent neutral amino acid transporter B(0)AT1</span> Protein-coding gene in the species Homo sapiens

Sodium-dependent neutral amino acid transporter B(0)AT1 is a protein that in humans is encoded by the SLC6A19 gene.

<span class="mw-page-title-main">SLC6A18</span> Protein-coding gene in the species Homo sapiens

Solute carrier family 6, member 18 also known as SLC6A18 is a protein which in humans is encoded by the SLC6A18 gene.

<span class="mw-page-title-main">SLC6A20</span> Protein-coding gene in the species Homo sapiens

Solute carrier family 6, member 20 also known as SLC6A20 is a protein which in humans is encoded by the SLC6A20 gene.

<span class="mw-page-title-main">Proton-coupled amino acid transporter 2</span> Protein-coding gene in the species Homo sapiens

Proton-coupled amino acid transporter 2 is a protein which in humans is encoded by the SLC36A2 gene.

<span class="mw-page-title-main">Monocarboxylate transporter 10</span> Protein-coding gene in the species Homo sapiens

Monocarboxylate transporter 10, also known as aromatic amino acid transporter 1 and T-type amino acid transporter 1 (TAT1) and solute carrier family 16 member 10 (SLC16A10), is a protein that in humans is encoded by the SLC16A10 gene. SLC16A10 is a member of the solute carrier family.

Dicarboxylic aminoaciduria is a rare form of aminoaciduria which is an autosomal recessive disorder of urinary glutamate and aspartate due to genetic errors related to transport of these amino acids. Mutations resulting in a lack of expression of the SLC1A1 gene, a member of the solute carrier family, are found to cause development of dicarboxylic aminoaciduria in humans. SLC1A1 encodes for EAAT3 which is found in the neurons, intestine, kidney, lung, and heart. EAAT3 is part of a family of high affinity glutamate transporters which transport both glutamate and aspartate across the plasma membrane.

<span class="mw-page-title-main">Hereditary folate malabsorption</span> Medical condition

Hereditary folate malabsorption (HFM) is a rare autosomal recessive disorder caused by loss-of-function mutations in the proton-coupled folate transporter (PCFT) gene, resulting in systemic folate deficiency and impaired delivery of folate to the brain.

<span class="mw-page-title-main">Proton-coupled folate transporter</span> Mammalian protein found in Homo sapiens

The proton-coupled folate transporter is a protein that in humans is encoded by the SLC46A1 gene. The major physiological roles of PCFTs are in mediating the intestinal absorption of folate, and its delivery to the central nervous system.

Proton-coupled amino acid transporters belong to the SLC26A5 family; they are protein receptors whose main function is the transmembrane movement of amino acids and their derivatives. This family of receptors is most commonly found within the luminal surface of the small intestine as well as in some lysosomes. The solute carrier family (SLC) of genes includes roughly 400 membrane proteins that are characterized by 66 families in total. The SLC36 family of genes maps to chromosome 11. The diversity of these receptors is vast, with the ability to transport both charged and uncharged amino acids along with their derivatives. In research and practice, SLC36A1/2 are both targets for drug-based delivery systems for a wide range of disorders.

In organic chemistry, secondary amino acids are amino acids which do not contain the amino group −NH2 but is rather a secondary amine. Secondary amino acids can be classified to cyclic acids, such as proline, and acyclic N-substituted amino acids.

References

  1. ↑ Ohura T (1998). "Familial iminoglycinuria". Ryoikibetsu Shokogun Shirizu (19 Pt 2): 569–571. PMID   9645136.
  2. 1 2 Statter M, Ben-Zvi A, Shina A, Schein R, Russell A (August 1976). "Familial iminoglycinuria with normal intestinal absorption of glycine and imino acids in association with profound mental retardation, a possible "cerebral phenotype"". Helvetica Paediatrica Acta. 31 (2): 173–182. ISSN   0018-022X. PMID   955941.
  3. 1 2 3 Rosenberg LE, Durant JL, Elsas LJ (June 1968). "Familial iminoglycinuria. An inborn error of renal tubular transport". New England Journal of Medicine. 278 (26): 1407–13. doi:10.1056/NEJM196806272782601. PMID   5652624.
  4. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 Bröer S, Bailey CG, Kowalczuk S, Ng C, Vanslambrouck JM, Rodgers H, Auray-Blais C, Cavanaugh, JA, Bröer A, Rasko JE (November 2008). "Iminoglycinuria and hyperglycinuria are discrete human phenotypes resulting from complex mutations in proline and glycine transporters" (Free full text). The Journal of Clinical Investigation. 118 (12): 3881–92. doi:10.1172/JCI36625. PMC   2579706 . PMID   19033659.
  5. 1 2 3 4 Miyauchi S, Abbot EL, Zhuang L, Subramanian R, Ganapathy V, Thwaites DT (November 2005). "Isolation and function of the amino acid transporter PAT1 (slc36a1) from rabbit and discrimination between transport via PAT1 and system IMINO in renal brush-border membrane vesicles". Molecular Membrane Biology. 22 (6): 549–559. doi:10.1080/09687860500421779. PMID   16373326. S2CID   40085087.
  6. 1 2 Coşkun T, Ozalp I, Tokatli A (April 1993). "Iminoglycinuria: a benign type of inherited aminoaciduria". The Turkish Journal of Pediatrics. 35 (2): 121–125. ISSN   0041-4301. PMID   7504361.
  7. 1 2 3 Online Mendelian Inheritance in Man (OMIM): Iminoglycinuria - 242600
  8. ↑ Camargo SM, Bockenhauer D, Kleta R (April 2008). "Aminoacidurias: Clinical and molecular aspects". Kidney International. 73 (8): 918–925. doi: 10.1038/sj.ki.5002790 . ISSN   0085-2538. PMID   18200002.
  9. ↑ Lasley L, Scriver CR (January 1979). "Ontogeny of amino acid reabsorption in human kidney. Evidence from the homozygous infant with familial renal iminoglycinuria for multiple proline and glycine systems". Pediatric Research. 13 (1): 65–70. doi: 10.1203/00006450-197901000-00014 . ISSN   0031-3998. PMID   432003.
  10. ↑ Weinberger B, Hanna N, Laskin JD, Heck DE, Gardner CR, Gerecke DR, Laskin DL (February 2005). "Mechanisms mediating the biologic activity of synthetic proline, glycine, and hydroxyproline polypeptides in human neutrophils" (Free full text). Mediators of Inflammation. 2005 (1): 31–38. doi: 10.1155/MI.2005.31 . PMC   1513057 . PMID   15770064.
  11. ↑ Proline at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
  12. 1 2 v. Sengbusch, Peter (2004). "Biosyntheses: Amino Acids". The Cell's Basic Metabolism. Botany online –The Internet Hypertextbook.
  13. ↑ "Proline P (Pro)". Biochemistry § The Chemistry of Amino Acids. The Biology Project, Department of Biochemistry and Molecular Biophysics, University of Arizona. 2003.
  14. 1 2 Procopis PG, Turner B (September 1971). "Iminoaciduria: a benign renal tubular defect". The Journal of Pediatrics. 79 (3): 419–422. doi:10.1016/S0022-3476(71)80150-6. ISSN   0022-3476. PMID   5567964.
  15. 1 2 Online Mendelian Inheritance in Man (OMIM): 138500
  16. 1 2 Tancredi F, Guazzi G, Auricchio S (March 1970). "Renal iminoglycinuria without intestinal malabsorption of glycine and imino acids". The Journal of Pediatrics. 76 (3): 386–392. doi:10.1016/S0022-3476(70)80477-2. ISSN   0022-3476. PMID   5308714.
  17. ↑ Greene ML, Lietman PS, Rosenberg LE, Seegmiller JE (February 1973). "Familial hyperglycinuria. New defect in renal tubular transport of glycine and imino acids". The American Journal of Medicine. 54 (2): 265–271. doi:10.1016/0002-9343(73)90232-5. ISSN   0002-9343. PMID   4685850.
  18. ↑ Kaser H, Cottier P, Antener I (September 1962). "Glucoglycinuria, a new familial syndrome". The Journal of Pediatrics. 61 (3): 386–394. doi:10.1016/S0022-3476(62)80369-2. ISSN   0022-3476. PMID   14454131.
  19. 1 2 3 Saito T, Hayasaka S, Yabata K, Omura K, Mizuno K, Tada K (November 1981). "Atypical gyrate atrophy of the choroid and retina and iminoglycinuria". The Tohoku Journal of Experimental Medicine. 135 (3): 331–332. doi: 10.1620/tjem.135.331 . ISSN   0040-8727. PMID   7314117.
  20. ↑ Weleber RG, Kennaway NG, Buist NR (August 1981). "Gyrate atrophy of the choroid and retina. Approaches to therapy". International Ophthalmology. 4 (1–2): 23–32. doi:10.1007/BF00139577. ISSN   0165-5701. PMID   7028650. S2CID   26071922.
  21. ↑ Rinaldi E, Stoppoloni GP, Savastano S, Russo S, Cotticelli L (March 1979). "Gyrate atrophy of choroid associated with hyperornithinaemia: report of the first case in Italy". Journal of Pediatric Ophthalmology and Strabismus. 16 (2): 133–5. doi:10.3928/0191-3913-19790301-12. ISSN   0191-3913. PMID   458520.
  22. ↑ Saito T, Omura K, Hayasaka S, Nakajima H, Mizuno K, Tada K (December 1981). "Hyperornithinemia with gyrate atrophy of the choroid and retina: a disturbance in de novo formation of proline". The Tohoku Journal of Experimental Medicine. 135 (4): 395–402. doi: 10.1620/tjem.135.395 . ISSN   0040-8727. PMID   7336429.
  23. ↑ De Vries A, Kochwa S, Lazebnik J, Frank M, Djaldetti M (September 1957). "Glycinuria, a hereditary disorder associated with nephrolithiasis". The American Journal of Medicine. 23 (3): 408–415. doi:10.1016/0002-9343(57)90320-0. ISSN   0002-9343. PMID   13458205.
  24. ↑ Oberiter V, Puretić Z, Fabecić-Sabadi V (April 1978). "Hyperglycinuria with nephrolithiasis". European Journal of Pediatrics. 127 (4): 279–285. doi:10.1007/BF00493544. ISSN   0340-6199. PMID   668712. S2CID   32224980.
  25. ↑ Scriver CR, Arthus MF, Bergeron M (August 1982). "Neonatal iminoglycinuria: evidence that the prolinuria originates in selective deficiency of transport activity in the proximal nephron". Pediatric Research. 16 (8): 684–7. doi: 10.1203/00006450-198208000-00022 . ISSN   0031-3998. PMID   7110792.
  26. 1 2 3 Takanaga H, Mackenzie B, Suzuki Y, Hediger MA (March 2005). "Identification of mammalian proline transporter SIT1 (SLC6A20) with characteristics of classical system imino". The Journal of Biological Chemistry. 280 (10): 8974–84. doi: 10.1074/jbc.M413027200 . ISSN   0021-9258. PMID   15632147.
  27. 1 2 3 Kowalczuk S, Bröer A, Munzinger M, Tietzel N, Klingel K, Bröer S (March 2005). "Molecular cloning of the mouse IMINO system: an Na+- and Cl--dependent proline transporter". The Biochemical Journal. 386 (Pt 3): 417–422. doi:10.1042/BJ20050100. PMC   1134859 . PMID   15689184.
  28. ↑ Castagna M, Shayakul C, Trotti D, Sacchi VF, Harvey WR, Hediger MA (January 1997). "Molecular characteristics of mammalian and insect amino acid transporters: implications for amino acid homeostasis". The Journal of Experimental Biology. 200 (Pt 2): 269–286. doi:10.1242/jeb.200.2.269. ISSN   0022-0949. PMID   9050235.
  29. ↑ Anderson CM, Grenade DS, Boll M, Foltz M, Wake KA, Kennedy DJ, Munck LK, Miyauchi S, Taylor PM, Campbell FC, Munck BG, Daniel H, Ganapathy V, Thwaites DT (November 2004). "H+/amino acid transporter 1 (PAT1) is the imino acid carrier: An intestinal nutrient/drug transporter in human and rat". Gastroenterology. 127 (5): 1410–22. doi:10.1053/j.gastro.2004.08.017. ISSN   0016-5085. PMID   15521011.
  30. 1 2 3 Thwaites DT, Anderson CM (February 2007). "Deciphering the mechanisms of intestinal imino (and amino) acid transport: the redemption of SLC36A1". Biochimica et Biophysica Acta (BBA) - Biomembranes. 1768 (2): 179–197. doi: 10.1016/j.bbamem.2006.10.001 . ISSN   0006-3002. PMID   17123464.
  31. ↑ Bröer A, Cavanaugh JA, Rasko JE, Bröer S (January 2006). "The molecular basis of neutral aminoacidurias". Pflügers Archiv: European Journal of Physiology. 451 (4): 511–7. doi:10.1007/s00424-005-1481-8. ISSN   0031-6768. PMID   16052352. S2CID   43517786.
  32. ↑ Ristic Z, Camargo SM, Romeo E, Bodoy S, Bertran J, Palacin M, Makrides V, Furrer EM, Verrey F (April 2006). "Neutral amino acid transport mediated by ortholog of imino acid transporter SIT1/SLC6A20 in opossum kidney cells". American Journal of Physiology. Renal Physiology. 290 (4): F880–7. doi:10.1152/ajprenal.00319.2005. PMID   16234310.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.